Neoleukin Therapeutics, Inc. (NLTX) Research

Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.

Market snapshot

Symbol
NLTX
Price
$3.49
Day change
+1.45%
Market cap
$8.2M
P/E ratio
-0.79x
52-week range
3.42-18.8
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Biora Therapeutics, Inc. (BIOR)
  • Channel Therapeutics Corporation (CHRO)
  • Centogene N.V. (CNTG)
  • COSCIENS Biopharma Inc. (CSCI)
  • DMK Pharmaceuticals Corporation (DMKPQ)
  • Lannett Company, Inc. (LCI)
  • Omega Therapeutics, Inc. (OMGA)
  • ProSomnus, Inc. (OSA)

Recent insider activity

  • Woods Robert Keith — A-Award (15400 shares) on 2024-01-16
  • PALEKAR ROHAN — A-Award (15400 shares) on 2024-01-16
  • Noonberg Sarah B. — A-Award (15400 shares) on 2024-01-16
  • Freedland Cory S. — A-Award (15400 shares) on 2024-01-16
  • BAFFI ROBERT — A-Award (15400 shares) on 2024-01-16

Open Neoleukin Therapeutics, Inc. (NLTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.